Budzik, Karol M.
Nace, Rebecca A.
Ikeda, Yasuhiro
Russell, Stephen J. http://orcid.org/0000-0002-0799-6432
Funding for this research was provided by:
Mayo Foundation for Medical Education and Research
U.S. Department of Health & Human Services | National Institutes of Health (T32 AI132165)
Article History
Received: 16 July 2021
Revised: 21 December 2021
Accepted: 25 January 2022
First Online: 10 February 2022
Competing interests
: SJR is a cofounder and stockholder in Vyriad, a privately held oncolytic virotherapy company, where he currently serves as the chief executive officer. Mayo Clinic also holds an equity stake in Vyriad. A patent application has been filed in relation to the technology described in the manuscript.